JNJ
JOHNSON & JOHNSONPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 20 to Feb 27 ▼ 2 days of insider sells: $1.3M by 2 insiders, avg $247.33
- Apr 14 ▲ Johnson & Johnson reported Q1 2026 earnings with adjusted EPS of $2.…
- Jun 11 ▼ 1 insider sell $2.4M at $241.15
- Jun 30 ▲ 8 funds open new positions (13F)
- Jul 20 ▼ 1 insider sell $5.8M at $251.27
- Aug 5 to Aug 17 ▼ 4 days of insider sells: $52.8M by 3 insiders, avg $260.28
- Sep 2 ▼ 1 insider sell $9.2M at $274.74
- Sep 4 to Sep 8 ▲ 2 buys: Ro Khanna, Lloyd Doggett bought, last disclosed Oct 9
- Sep 24 Owens et al v. Johnson & Johnson et al
- Sep 30 to Oct 7 ▼ 2 sells: Thomas Kean Jr, Ro Khanna sold, last disclosed Nov 9
- Nov 3 Trial readout: Results Pending: Rilpivirine (Phase 2), completed 77d ago
- Nov 12 ▼ 1 insider sell $3.7M at $284.39
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $75.2M.
- InstitutionsBULLISH
Q2 2026: 57 added (8 new), 32 trimmed or exited. Largest new: Hrt Financial $262.1M, Polar Capital Holdings $199.0M.
- AnalystsBULLISH
21 of 30 rate it Buy or better. Median target $280.50 (−1%).
- Short sellersSTEADY
Short interest +1.8% to 17.07M shares. 2.4 days to cover, ≈0.7% of shares.
- TrendUPTREND
6% above its 50-day average. New closing high $285.75 on Nov 13.
- SocialQUIET
Crowd 67° (warm) this week from 8 mentions: 4 bullish, 0 bearish. No setup is alerting. Excludes 1 subscriber-only day.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | $5.8B |
| Capital World Investors | ADD | $3.9B |
| Fisher Asset Management, LLC | ADD | $3.4B |
| BARCLAYS PLC | TRIM | $1.2B |
| CITIGROUP INC | ADD | $996.9M |
| MARSHALL WACE, LLP | ADD | $759.3M |
| Bahl & Gaynor LLC | TRIM | $500.5M |
| Assenagon Asset Management S.A. | ADD | $492.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
30 analystsPrice is inside the target range. Median implies −1%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 16, 2026 | Wells Fargo MAINTAIN | Overweight |
| Oct 15, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 14, 2026 | Leerink Partners MAINTAIN | Outperform |
| Oct 14, 2026 | Wells Fargo MAINTAIN | Overweight |
| Oct 14, 2026 | RBC Capital MAINTAIN | Outperform |
| Oct 7, 2026 | Guggenheim REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Forminard Elizabeth EVP, Chief Legal Officer Nov 12, 2026 | EXERCISE | $2.0M |
Forminard Elizabeth EVP, Chief Legal Officer Nov 12, 2026 | SELL | $3.7M |
HEWSON MARILLYN A Director Sep 8, 2026 | AWARD | $50.0K |
Woods Eugene A. Director Sep 8, 2026 | AWARD | $37.5K |
Pinto Daniel E Director Sep 8, 2026 | AWARD | $31.3K |
Schmid Timothy EVP, WW Chair, MedTech Sep 2, 2026 | EXERCISE | $1.5M |
Schmid Timothy EVP, WW Chair, MedTech Sep 2, 2026 | SELL | $3.0M |
Schmid Timothy EVP, WW Chair, MedTech Sep 2, 2026 | EXERCISE | $3.4M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
21 filings · 4 bullish · 2 bearish · 3 mixed · 12 neutral- MIXED INST-CLUSTERNov 16, 2026
In the 2026-Q3 13F filings, 27 institutions increased their JNJ positions by a net $3.73B, while 15 reduced holdings by $984.9M, resulting in a mixed net conviction. The buying is led by Capital World Investors, which added $3.10B, but the cluster is dominated by asset managers and includes…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 12, 2026
Elizabeth Forminard, an officer of Johnson & Johnson, filed a Form 144 notice of intent to sell…
The filing is a routine advance notice of an insider sale. The small size relative to market cap and the officer's role suggest no material signal. Monitor for any subsequent Form 4 filings to…
- MIXED 8-KOct 13, 2026
JNJ reported Q3 2026 adjusted EPS of $2.59, a -11.2% miss vs consensus of $2.92, and revenue of…
The headline EPS and revenue miss vs consensus is a negative surprise, but the guidance raise signals management sees underlying operational strength. Watch the earnings call for details on talc…
- BULLISH COURT-RULINGSep 30, 2026
JNJ subsidiary Janssen Biotech won summary judgment in a decade-old qui tam False Claims Act suit…
This is a final judgment on the merits, the case is over unless relator appeals to the First Circuit. Monitor for any notice of appeal within 30 days. The ruling removes a long-standing overhang…
All JNJ filing & press-release reports (21)
- INST-CLUSTER reportNov 16, 2026
- 144 reportNov 12, 2026
- 8-K reportOct 13, 2026
- COURT-RULING reportSep 30, 2026
- COURT-RULING reportSep 24, 2026
- COURT-RULING reportSep 9, 2026
- CLUSTER reportAug 18, 2026
- CLUSTER reportAug 14, 2026
- COURT-RULING reportAug 7, 2026
- CLUSTER reportAug 7, 2026
- 8-K reportAug 4, 2026
- COURT-RULING reportJul 22, 2026
- 8-K reportJul 15, 2026
- COURT-RULING reportApr 29, 2026
- COURT-RULING reportMay 20, 2026
- Leerink Partners double upgrades to Outperform, PT $265 (+18%)May 13, 2026
- COURT-RULING reportMay 5, 2026
- 8-K reportApr 14, 2026
- COURT-RULING reportMar 30, 2026
- DEFA14A reportMar 11, 2026
- INST-CLUSTER reportFeb 28, 2026